Derbyshire Medicines Management
and Clinical Policies
This page contains documents relating specifically to the AstraZeneca COVID-19 vaccine
National protocol for COVID-19 vaccine AstraZeneca
National protocol for COVID-19 vaccine Vaxzevria
AstraZeneca and blood clot information
Public Health England COVID-19 vaccination and blood clotting
FAQ: MHRA and JCVI guidance on AstraZeneca COVID-19 vaccine and very rare clotting disorders
All suspected cases report to both the MHRA on the COVID-19 Yellow Card scheme and to PHE’s clinical reporting scheme at https://cutt.ly/haem_AE
AstraZeneca COVID-19 vaccine information
|
Gov.uk - Regulatory approval of COVID-19 AstraZeneca vaccine |
Regulatory approval of COVID-19 AstraZeneca vaccine |
|
Patient Group Direction for COVID-19 AstraZeneca vaccine Patient Group Direction for COVID-19 Vaxzevria vaccine
|
Patient Group Direction for COVID-19 AstraZeneca vaccine
|
|
Patient Specific Direction AstraZeneca vaccine (for local adoption) |
Individual assessment to assist the creation of Patient Specific Direction for the administration of COVID-19 AstraZeneca vaccine |
|
AstraZeneca Vaccine Ingredients |
AstraZeneca Vaccine Ingredients |
|
Position Statement - use of AstraZeneca to vaccinate housebound patients |
Position statement around the use of COVID-19 vaccine AstraZeneca to vaccinate housebound patients |
| Patient Information Leaflet |
Patient Information Leaflet for COVID-19 vaccine AstraZeneca |
| Summary of Product Characteristics |
Summary of Product Characteristics for COVID-19 vaccine AstraZeneca |
|
Support channels for healthcare professionals and recipients of the vaccine |
Website - www.azcovid-19.com Telephone - 0800 054 1028 England: For any questions in relation to the supply of COVID-19 vaccines, please contact |
SPS Astra Zenenca information
